Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Lung infection is the main cause of disease in CF patients. New ways to identify germs that cause lunginfections based on analysis of DNA have uncovered more germs than expected. This includes germs thatcannot live in air, but can live in mucus. Therefore we want to understand how these new germs are relatedto CF disease. We are interested in tracking the amount of each germ present in the lung during periods ofstable lung function and during exacerbation. The goal of the project is to understand how each germ foundin the lungs of CF patients is involved in disease and the best way to treat lung infections in CF.
>= 6 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
FOR MORE INFORMATION:
Sponsor Contact Information:
Harris, Jonathan (303) 735-1808 email@example.com
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.